Multiple Myeloma in Relapse
86
24
33
17
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
11 trials with published results (13%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.1%
7 terminated out of 86 trials
70.8%
-15.7% vs benchmark
5%
4 trials in Phase 3/4
65%
11 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (86)
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Ixazomib + Pomalidomide + Dexamethasone In MM
TriPRIL CAR T Cells in Multiple Myeloma
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse
Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001)
Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma
Universal CAR-T Cell Therapy for MM
Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma Patients
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma
UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma